Activated allogeneic NK cells preferentially kill poor prognosis B-cell chronic lymphocytic leukemia cells

Activated allogeneic NK cells preferentially kill poor prognosis B-cell chronic lymphocytic leukemia cells

Mutational status of TP53 together with expression of wild type (wt) IGHV represents the most widely accepted biomarkers, establishing a very poor prognosis in B-cell chronic lymphocytic leukemia (B-CLL) patients. Adoptive cell therapy using allogeneic HLA mismatched Natural Killer (NK) cells has em...

Full description

Bibliographic Details
Main Authors: Diego Sanchez-Martinez, Pilar Lanuza, Natalia Gomez, Aura Muntasell, Elisa Cisneros Leralta, Manuela Moraru, Gemma Azaceta, Alberto Anel, Luis Martínez-Lostao, Martin Villalba, Luis Palomera, Carlos Vilches, Jose A García Marco, Julian Pardo
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-10-01
Series:Frontiers in Immunology
Subjects:
mismatch
chronic lymphocytic leukemia
Allogeneic NK cells
Bad prognosis leukemia
leukemia resistance
Online Access:http://journal.frontiersin.org/Journal/10.3389/fimmu.2016.00454/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fimmu.2016.00454/full

Similar Items